Mechanism deep-dive

One precision pathway.

A single nanovesicle platform takes an active from the skin's surface to the layer where it works, releasing it gradually without breaking the barrier it passes through.

01 Penetration pathway

Four stages, surface to target

Answer first

Cetosome® delivery has four stages. The formulation is applied as a film of intact vesicles. The vesicles move through the stratum corneum along its intercellular lipid route. They break into smaller units that diffuse slowly through the viable epidermis. The active is then released in the layer where it works. Move the slider to follow each stage.

Cross-section of skin showing Cetosome® penetration from surface to dermis in four stagesSurface filmStratum corneumViable epidermisDermis

Stage 1 · depth 0 µm

Surface Application

The formulation spreads as a film of intact nanovesicles in a water-rich (≥40%) base. The active is still inside the vesicle, shielded from air and light, and almost none of it touches the skin as free molecules.

Vesicle-bound active; minimal free fraction

Fig. 2One precision pathway, in four stages. Skin layers are schematic and depths are typical values for facial and forearm skin. The mechanism is described in the granted patent text (no permanent disruption of the stratum corneum; disassembly into smaller penetration units).

Mechanism as described in the granted patent text[1]. For stratum corneum structure see[3]; for molecular-size limits see [4].

02 Release profile

24 hours, not one burst

Answer first

Conventional vehicles release most of their active within the first hour. That early spike crosses the threshold where stinging and erythema begin, and the level then falls below the effective range within hours. A vesicle reservoir releases the same active gradually, holding a moderate, steady level across most of the day.

Move across the chart to read values

Relative active concentration at the target layer over 24 hoursThe conventional vehicle peaks at 100 within the first hour, above the irritation threshold, then falls below the effective window by about hour 5. The Cetosome profile rises over two hours to about 46 and stays inside the effective window until about hour 23.Irritation threshold (stinging, erythema)Effective window02550751000h2h4h6h8h12h16h20h24hHours after application →Relative concentrationBurst peakInside window ≈ 2–23 h
View as table
HourConventionalCetosome®
0.597.53.3
195.19.5
268.721.1
434.234.4
88.443.2
122.145.3
160.545.9
200.146
24022.8
Fig. 3Illustrative model, not measured data. A one-compartment model compares a single-bolus vehicle (first-order absorption) with near-continuous input from a vesicle reservoir, using the same elimination rate. Curves are scaled for shape (conventional peak = 100), so the areas are not dose-equivalent. Threshold and window lines are conceptual. The release claim of up to 24 hours comes from the platform specification and the patent's animal (rabbit) pharmacokinetic study.

03 Core properties

Three properties that make it work

Answer first

The platform rests on three properties. First, a self-assembling lamellar structure built from cetylated components. Second, dual solubility, so water- and oil-soluble actives share one particle. Third, lipid compatibility with the skin barrier's own ceramide, cholesterol and fatty-acid architecture. Together they allow deeper, gentler and slower delivery than solvent-driven vehicles.

01 · Structure

Self-assembling nanovesicle

Hydrocarbon chains of cetylated esters and fatty alcohols align into a birefringent lamellar core, with a surfactant and polar-solvent corona facing the water phase.[1]

02 · Solubility

Hydrophilic + lipophilic

Polar actives sit in the solvent-rich mantle and non-polar actives in the lamellae. Oil-loaded batches form a second, larger particle population around the oil phase.[1]

03 · Lipid compatibility

Biomimetic of the barrier

The lipid bilayer resembles the stratum corneum's ceramide–cholesterol–fatty-acid mortar[3], so it delivers without the permanent barrier disruption caused by chemical enhancers.[1]

04 Technical specifications

Conventional vehicle vs. Cetosome® platform

Answer first

Compared with a conventional cream or serum, the Cetosome® platform reaches more layers and releases over up to 24 hours instead of in one burst. It supports the barrier rather than disrupting it, carries both solubility classes, and has quantified physical specifications: 60–850 nm diameter, −20 to −100 mV claimed charge, and 18–26 months of real-time stability.

Technical specification comparison
SpecificationConventionalCetosome®
PenetrationSurface, limited depthMulti-layer, follows the intercellular lipid route
Release profileRapid burst, then declineControlled, up to 24 hours
Barrier impactEnhancers often fluidise or extract lipidsBiomimetic; no permanent barrier disruption
Active solubilityHydrophilic or lipophilic per vehicleBoth, on one platform
Oxidation protectionActive exposed in filmShielded within lipid lamellae
Particle diameterEmulsion droplets ~1–20 µm60–850 nm measured (claims 30 nm–5 µm)
Surface charge (ζ)Not engineered−20 to −100 mV claimed; −22 to −55 mV measured
pH toleranceFormulation-specificStable across pH 4–10
Real-time stabilityVaries18–26 months at 25 °C / 65% RH
Solvent loadOften ethanol / propylene glycolEthanol- and PG-free formulations demonstrated

Cetosome® specifications from US 9,084,818 B2[1]. Zeta potential measurement depends on conditions; see [7]. For the clinical meaning of size and PDI see[6].

05 Size & morphology

Where Cetosomes® sit on the nanocarrier scale

Answer first

Topical carriers span four orders of magnitude, from 30 nm exosomes to microspheres hundreds of microns across. Cetosomes® occupy the 60–850 nm nanovesicle band, often as two populations: a small, empty-core particle and a larger, oil-cored particle. Particle size matters less than whether the carrier stays stable and releases reproducibly.

Typical size ranges of topical carrier systems on a logarithmic scaleCetosome®: 60–850 nm (measured). Transfersomes: ~100–300 nm (typical). Ethosomes: ~100–400 nm (typical). Liposomes: ~50 nm – several µm. Niosomes: ~100 nm – 2 µm. Exosomes (EVs): ~30–150 nm. Microspheres: ~1–250 µm. Unencapsulated actives: Emulsion droplets ~1–20 µm.10 nm100 nm1 µm10 µm100 µmNano domain (< 1 µm)Cetosome®60–850 nm (measured)Transfersomes~100–300 nm (typical)Ethosomes~100–400 nm (typical)Liposomes~50 nm – several µmNiosomes~100 nm – 2 µmExosomes (EVs)~30–150 nmMicrospheres~1–250 µmUnencapsulated activesEmulsion droplets ~1–20 µm
Fig. 4Typical size ranges reported in the cited literature (log scale). Cetosome® range is the measured 60–850 nm from US 9,084,818 B2. The patent claims cover physical dimensions of 30 nm–5 µm. Individual formulations vary.

Frequently asked

How do cetosomes penetrate the skin?

Cetosomes are applied in a water-rich base. They move through the stratum corneum along its intercellular lipid route without permanently disrupting barrier function, then break into smaller penetration units that release their cargo gradually through the viable epidermis to the target layer.

What does 24-hour controlled release mean?

Instead of releasing most of the active at once, the vesicle reservoir delivers it over many hours. This keeps concentrations inside the effective range for longer and avoids the early peak associated with stinging and erythema. In the patent's animal pharmacokinetic study (rabbits), drug levels stayed above 2 ng/mL for most of a 24-hour observation period.

What are the technical specifications of a Cetosome?

Measured particle diameters of 60–850 nm (claims cover 30 nm–5 µm). Zeta potential claimed at −20 to −100 mV, with −22 to −55 mV measured across formulations. Stable at pH 4–10, with real-time stability of 18–26 months at 25 °C / 65% RH. Composition: 4–20% cetylated esters, surfactants, polar solvents and at least 40% water.


References

  1. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  2. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US Patent US 8,394,759 B2. 2013.Priority 21 Nov 2008; filed 29 Oct 2009; granted 12 Mar 2013. Foundational cetylated-fatty-ester penetrant work, incorporated by reference into US 9,084,818 B2.
  3. Elias PM. Stratum Corneum Defensive Functions: An Integrated View. Journal of Investigative Dermatology 125(2):183–200. 2005.DOI 10.1111/j.0022-202X.2005.23668.x
  4. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x
  5. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics 332(1–2):1–16. 2007.DOI 10.1016/j.ijpharm.2006.12.005
  6. Danaei M, Dehghankhold M, Ataei S, et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 10(2):57. 2018.DOI 10.3390/pharmaceutics10020057
  7. Bhattacharjee S. DLS and zeta potential — What they are and what they are not?. Journal of Controlled Release 235:337–351. 2016.DOI 10.1016/j.jconrel.2016.06.017
  8. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology 26(11):1261–1268. 2008.DOI 10.1038/nbt.1504

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.